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Evaluation of antidiabetic properties of Momordica charantia in 
streptozotocin induced diabetic rats using metabolomics approach
Abstract
Momordica charantia, also known as bitter melon or ‘peria katak’ in Malaysia, is a member 
of the family Cucurbitaceae. Bitter melon is an excellent source of vitamins and minerals that 
made it extensively nutritious. Moreover, the seed, fruit and leave of the plant contain bioactive 
compounds with a wide range of biological activities that have been used in traditional 
medicines in the treatment of several diseases, including inflammation, infections, obesity and 
diabetes. The aim of this study was to evaluate changes in urinary metabolite profile of the 
normal, streptozotocin-induced type 1 diabetes and M. charantia treated diabetic rats using 
proton nuclear magnetic resonance (1H-NMR) -based metabolomics profiling. Study had been 
carried out by inducing diabetes in the rats through injection of streptozotocin, which exhibited 
type 1 diabetes. M. charantia extract (100 and 200 mg/kg body weight) was administrated to the 
streptozotocin-induced diabetic rats for one week. Blood glucose level after administration was 
measured to examine hypoglycemic effect of the extract. The results obtained indicated that M. 
charantia was effective in lowering blood glucose level of the diabetic rats. The loading plot of 
Partial Least Square (PLS) component 1 showed that diabetic rats had increased levels of lactate 
and glucose in urine whereas normal and the extract treated diabetic rats had higher levels of 
succinate, creatine, creatinine, urea and phenylacetylglycine in urine. While the loading plot of 
PLS component 2 showed a higher levels of succinate, citrate, creatine, creatinine, sugars, and 
hippurate in urine of normal rat compared to the extract treated diabetic rat. Administration of 
M. charantia extract was found to be able to regulate the altered metabolic processes. Thus, it 
could be potentially used to treat the diabetic patients.
Introduction
Prevalence of diabetes mellitus is increasing at 
an alarming rate globally. Recent estimates indicates 
171 million people in the world with diabetes in the 
year of 2000 and this is projected to increase to 366 
million by the year of 2030 (Wild et al., 2004) The 
health consequences of diabetes become increasingly 
overwhelming the health care systems due to the 
severity of the long term complications of diabetes 
(Noor et al., 2008). Diabetes mellitus is a metabolic 
disorder that is characterized by hyperglycemia 
resulting from inadequate insulin secretion (type 
1 diabetes mellitus) or insulin insensitivity (type 2 
diabetes mellitus) (Bastaki et al., 2005). 
Several synthetic drugs such as sulfonylureas 
and biguanides are available as an oral hypoglycemic 
agent to lower blood glucose level in diabetics. 
However, their administration might give side effect 
to the patients (Noor et al.,2008). Therefore, the 
finding of new prevention strategies and treatments 
for diabetes is urgent. Nowadays, many researches 
are carried out to explore plant natural products that 
contain certain phytochemicals with anti-diabetic 
potential as the alternative therapy (Noor et al., 2008). 
One of such herbal plants is Momordica charantia.
Momordica charantia, also known as bitter melon, 
is a member of the cucumber family, Cucurbitaceae. 
It is grown in the tropical and subtropical regions of 
the world. All parts of the plant, including the fruit, 
taste bitter. Fruits and seeds of bitter melon possess 
medicinal properties such as anti-HIV, anti-ulcer, 
anti-inflammatory, anti-leukemic, anti-microbial, 
anti-tumor and anti-diabetic activity. It can be used 
as alternative therapy for lowering blood glucose 
levels in diabetic patients (Taylor et al., 2002). 
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This is attributed to the complex action of multiple 
compounds in bitter melon extract (Basch et al., 
2003). The bioactive compounds responsible for 
its hypoglycemic effect are a mixture of steroidal 
saponins known as charantins, insulin-like peptides 
and alkaloids (Raman et al., 1996). 
Metabolomics is the comprehensive 
measurement of all endogenous metabolites in a 
biological fluid (Lindon et al., 2007). Through this 
approach, changes in metabolites profile of the 
biofluids can be identified. Therefore, metabolomics 
have been applied to diagnose diabetic patients and 
to identify the potential biomarkers (Van Doorn et 
al., 2007). The same approach can be used to study 
the medicinal properties of herbs as well. Thus, the 
underlying mechanisms of alteration in metabolic 
pathway associated with mechanism of medicinal 
herbs to treat a disease can be identified (Zhang et 
al., 2012).
As diabetes has become a serious global health 
problem that getting more concern from nation 
worldwide, studies should be carried out to deliver 
the problem. Since there are lots of natural plant 
products that exhibit anti-diabetic potential, research 
should focus on herbal remedy as alternative therapy 
for diabetes treatment to reduce dependence on the 
synthetic drugs. One of such plants is M. charantia. 
However, the results of the previous research on 
M. charantia in the treatment of diabetes were still 
based on glucose and insulin analysis . More research 
needs to be done on a holistic analysis of metabolites 
in biofluids. The objective of this study was to 
evaluate changes in urinary metabolite profile of 
the normal, STZ-induced diabetes and M. charantia 
extract treated diabetic rats using 1H-NMR-based 
metabolomics profiling. 
Materials and Method
Chemicals 
Ethanol (Merck, Darmstadt, Germany), 
streptozotocin (Merck, Darmstadt, Germany), 
carboxymethylcellulose (Sigma-Aldrich, St. Louis, 
US), sodium azide (NaN3) (Merck, Darmstadt, 
Germany), imidazole (Merck, Darmstadt, Germany), 
deuterated oxide (D2O) (Sigma-Aldrich, St. Louis, 
US), Trimethylsilanepropionic acid sodium salt (TSP) 
(Merck, Darmstadt, Germany) and NaOD (Merck, 
Darmstadt, Germany) were used in this study.
Plant preparation
Fresh green unripe whole fruits of M. charantia 
harvested in May 2011 were collected from a farm 
at Teluk Intan, Malaysia. Identification of species 
was done  by Herbarium Institut of Biosains and the 
voucher number is SK/ 1931/11.Cleaning of bitter 
melon with water was carried out before removal of 
seeds and cutting into small pieces. Then the sample 
was ground cryogenically in liquid nitrogen. The 
ground sample was lyophilized using a freeze dryer 
(Freezone 6, Labconco, USA) and stored at -80ºC 
until extraction. 
Plant extraction
Extraction was carried out by referring to 
procedure of Virdi et al. (2003) with modification. 
The ground sample of M. charantia fruit was soaked 
in the ratio of 3:4 (w/v) in 80% ethanol (v/v) at room 
temperature for 24 h. The extract was then filtered 
and the residue re-extracted with 80% ethanol. The 
extraction process was repeated for three times. After 
filtration, the combined filtrates were evaporated to 
remove the solvent with a rotary evaporator (Buchi 
Rotavor R-200, Flawil, Switzerland) at 40ºC. The 
extract was freeze-dried and then preserved at -80ºC 
for later usage.
Preparation of animals 
Animal preparation was carried out according 
to the method of Jalil et al. (2009). Twelve male 
Sprague-Dawley rats, each weighing 100-250 g, 
were used. A study approval was obtained from 
Animal Care and Use Committee (ACUC) of the 
Faculty of Medicine and Health Sciences, Universiti 
Putra Malaysia (ACUC No: UPM/FPSK/PADS/
BRUUH/00407). The rats were placed in plastic 
cages with stainless steel cover. They were put 
under acclimatization conditions for a week at room 
temperature (26-28 ºC) under a 12 h light/12 h dark 
cycle. During the acclimatization period, all the 
rats were subjected to normal rat chow (Gold Coin, 
Selangor, Malaysia) and distilled water ad libitum. 
Following acclimatization, body weight of the rats 
was measured and the rats were divided randomly 
into four (n=3): group1(normal diet without STZ 
injection), group 2 (diabetic control with STZ 
injection), group 3 (100 mg/kg BW treated with M. 
charantia with STZ injection), group 4 (200mg/kg 
BW treated with M.charantia with STZ injection).
Rat induction of diabetes 
Following Amin et al. (2004), STZ was prepared 
in 0.05 M citrate buffer, pH 4.5. Rats were injected 
intravenously with STZ (25 mg/kg body weight) 
after acclimatization to induce diabetes. Blood 
was collected from the tail vein 3 days after STZ 
injection and its glucose level was determined with a 
glucometer (Roche, Mannheim, Germany) to ensure 
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the development of diabetes. The rats were considered 
diabetic if their blood glucose concentration was 
more than 13.9 mmol/L at that time (Thirumalai et 
al., 2011).
Administration of Momordica charantia extract 
M.charantia extract was suspended in 0.03% 
(w/v) of carboxymethylcellulose (CMC) and 
administered daily by gastric intubation using a force-
feeding needle for the duration of one week (Jalil et 
al., 2009). Rats in other groups received 0.03% (w/v) 
CMC throughout the experiment (Jalil et al., 2009). 
After 1 week administration of M. charantia extract 
or CMC to the respective groups, blood glucose level 
was determined at 0, 2, 4 and 6 h ( Yuan et al., 2008).
Collection of urine sample
Urine samples before and after treatment were 
collected in the tubes containing 0.1% sodium azide 
(as anti-microbial) by placing the rats in metabolic 
cages overnight. The collected urine samples were 
then stored frozen at -80°C until analysis (Zhoa et 
al., 2011).
Preparation of urine samples and acquisition of 
1H-NMR spectra
Thawed urine sample was centrifuged at 5000 
rpm for 10 minutes. 0.01 M phosphate buffer 
(KH2PO4) was made in D2O (pH 7.4) containing 
0.1% TSP and 0.1% of imidazole. The pH of the 
D2O was adjusted to 7.4 using a 1 M NaOD solution. 
Then 400 μl of the centrifuged urine sample was 
mixed with 200 μl of 0.01 M phosphate buffer (pH 
7.4) into 1.5 ml of eppendorf tube and sonicated for 
5 minutes (room temperature) to remove air bubbles. 
The urine solution was transferred into standard 5 
mm NMR tube (Beckonert et al., 2007). The NMR 
tube containing the urine sample was then inserted 
into a Varian INOVA 500 spectrometer (Illinois, 
USA). 1H-NMR spectra was recorded at 26°C and 
500 MHz with the following parameters: pulse width 
(PW) 21.0 μs (90°) and relaxation delay (RD) 2.0 s. 
Deuterium oxide was used as the internal lock. Each 
1H-NMR spectrum consisted of 64 scans requiring 
3 min and 26 s acquisition time. A pre-saturation 
sequence was used to suppress the residual water 
signal with low power selective irradiation. 
Data processing and statistical analysis
The resulting NMR spectra were manually 
phased and baseline-corrected and calibrated to TSP 
(internal standard) at 0.0 ppm. A spectral region from 
0.50-10.00 ppm was bucketed into 0.04-ppm-wide 
using Chenomx NMR software (Chenomx NMR 
Suite 5.1 Professional, Edmonton, Canada). Water 
(4.68–5.00 ppm) and imidazole (7.23-7.40, 8.43-
8.46 ppm) signals were excluded from the data. The 
spectra data were then converted to Microsoft Excel 
format and imported into SIMCA-P software (version 
12.0, Umetrics, Umea, Sweden) for multivariate 
data analysis. The bucketed data were perpetrated 
using MSC Filter and Pareto scaled. The data were 
statistically analyzed using partial least squares 
discriminant analysis (PLS-DA). The PLS-DA model 
was validated by permutation testing with describing 
R2 and Q2 values. Samples located out of Hotelling’s 
eclipses in the PLS-DA score plots were considered 
as outlier and excluded for further analysis.
Results of blood glucose level measured by 
glucometer were expressed as mean±standard 
deviation of 3 rats in each group. Statistical evaluation 
was done using one-way ANOVA, followed by 
Tukey’s test using Minitab (Minitab 16). Differences 
of p-value less than 0.05 were considered statistically 
significant. 
Results
As shown in Table 1, there was a significant 
difference in the mean blood glucose level between 
STZ-induced diabetic groups and normal control 
group (p < 0.05). The normal control group showed 
normal blood glucose level at 4.13±0.12 mmol/L, 
Table 1. Blood glucose level of rats at 3 days after 
STZ injection and one week after administration of M. 
charantia extract
Values are expressed as mean±standard deviation for 3 rats in 
each group. 
Means that do not share the same letter are significantly different 
(p<0.05). 
Upper case after mean values represents a statistical comparison 
through rows while lower case after mean values in superscript 
represents a statistical comparison through columns.
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whereas the blood glucose level of the diabetic groups 
was ranged from 25.00±4.62 mmol/L to 29.27±0.38 
mmol/L. Thus, it was evident that injection of STZ 
intravenously at a dosage of 25 mg/kg body weight 
caused a significant diabetogenic response in the 
rats. Administration of M. charantia extract resulted 
in a statistically significant reduction in mean 
blood glucose level in the diabetic rats (p < 0.05). 
The untreated diabetic rat had significantly higher 
blood glucose level than that of treated diabetic rats 
(p<0.05). Administration of M. charantia extract 100 
and 200 mg/kg body weight lowered blood glucose 
level of the diabetics to 7.93±6.50 mmol/L and 
4.40±0.76 mmol/L, respectively, with no significant 
difference between both dosage groups and normal 
control group at 6 h after second administration of 
M. charantia.
Urine samples collected from the normal, STZ-
induced type 1 diabetic and M. charantia treated 
diabetic rats were subjected to 1H-NMR. The bucketed 
data of all 1H-NMR spectra were used in conjunction 
with multivariate data analysis to examine metabolic 
changes in rat’s urines associated with diabetes and 
M. charantia treatment. The assignments of spectra 
Table 2. 1H-NMR chemical shifts of metabolites in urine 
from normal, diabetic control and MC extract treated 
diabetic rats (in ascending order of the signals in spectra)
* s = singlet, d = doublet, t = triplet, m = multiplet
Figure 1. 1H-NMR spectra of urine from a normal, 
diabetic control and MC extract treated diabetic rat. 
Identified metabolites: 1: 2-hydroxybutyrate; 2: leucine; 
3: 3-hydroxybutyrate; 4: lactate; 5: alanine; 6: acetate; 
7: succinate; 8: citrate; 9: dimethylamine; 10: creatine; 
11: creatinine; 12: glucose; 13: mixture of sugars; 
14: galactose+glucose; 15: allantoin; 16: urea; 17: 
phenylacetylglycine; 18: hippurate
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were made based on the database of Chenomx NMR 
software (Chenomx NMR Suite 5.1 Professional, 
Edmonton, Canada) and comparison to previous 
reports on the NMR spectra of urine metabolites 
(Zhao et al., 2010, Zhao et al., 2011; Liu et al., 2012). 
1H-NMR spectra of urine from a normal, 
diabetic control and M. charantia extract treated 
diabetic rat are shown in Figure 1along with the 
metabolites assignment. The spectra contained 
a number of signals such as 2-hydroxybutyrate, 
leucine, 3-hydroxybutyrate, lactate, alanine, 
acetate, succinate, citrate, dimethylamine, creatine, 
creatinine, glucose, sugars, galactose, allantoin, 
urea, phenylacetylglycine and hippurate. From the 
spectra, it is obvious that the urine of diabetic rat 
contained higher amount of glucose compared to 
those of normal and M. charantia  treated diabetic 
rats. Higher levels of lactate and acetate were also 
observed in urine of diabetic rat. However, levels of 
citrate, succinate, urea and hippurate were lower in 
urine of diabetic rat compared to those of normal and 
M. charantia treated diabetic rats.
Partial least square discriminant analysis (PLS-
DA) was selected among multivariate data analysis 
techniques in order to discriminate urine sample from 
different rat groups. The rat groups were treated as 
y variables in this regression technique. PLS-DA 
score plots (Figure 2) showed clustering of the rat 
groups in the first and second PLS components, with 
separation between the diabetic group of normal 
and M. charantia treated diabetic groups along the 
PLS component 1 that accounts for 49.62% of the 
variation. On the other hand, normal group separated 
from M. charantia treated diabetic groups along 
PLS component 2 that accounts for 21.44% of the 
variation. These two PLS component account for 
71.06% of the total variation. 
A value of R2Y shows the goodness of fit for the 
components, while Q2 indicated the predictive ability 
(Barker et al., 2003). R2Y is the percent of variation 
of the response explained by the model; Q2 is the 
percent of the variation of the response predicted by 
the model according to cross validation. This PLS-
DA model had R2Y value of 0.58 and Q2 of 0.41. 
The model was considered good since the difference 
between R2Y and Q2 was less than 0.3 (Eriksson et 
al., 2006). Permutation test was performed to validate 
the PLS-DA model. R2 intercept less than 0.3-0.4 and 
Q2 intercept less than 0.05 indicated the models are 
valid (Mazzara et al., 2011). The PLS-DA model had 
R2 intercept value of 0.161 and Q2 intercept value of 
-0.396. Thus, this PLS-DA model was considered 
valid. 
The loading column plot for PLS component 1 
is shown in Figure 3(A). The buckets in Figure 3(A) 
correspond to the 1H-NMR chemical shift binned in 
every 0.04 ppm interval, which leads to separation 
of the diabetic group from normal and M. charantia 
treated diabetic groups along PLS component 1 of the 
model. These buckets are assigned with metabolites 
based on the chemical shifts in Table 2.   
The loading column plot for PLS component 2 
is shown in Figure 3(B). It shows the corresponding 
Figure 2. PLS-DA score plot obtained using 1H-NMR 
data for the normal, diabetic control and MC treated 
diabetic groups. Outliers located out of Hotelling’s eclipse 
were excluded
Figure 3. The loading column plot for (A) PLS component 
1 and (B) PLS component 2 with jack-knifed confidence 
intervals. ‘MSC’ represents Multiplicative Signal 
Correction defined as normalization of each observation 
(spectra) by regressing it against the average spectrum 
and the value in x-axis represents the bucketed 1H-NMR 
chemical shift (ppm).
1303  Perumal et al./IFRJ 22(3): 1298-1306
variables that leads to separation of M.charantia 
treated diabetic groups from normal group along PLS 
component 2 of the model. As shown in Figure 3(B), 
there were higher levels of succinate, citrate, creatine, 
creatinine, sugar and hippurate in urine samples of 
normal rat compared to M. charantia treated diabetic 
rat. However, there were two unassigned metabolites 
with increased level in urine of M.charantia treated 
diabetic rats. The sugar signals were difficult to be 
assigned since it could be a mixture of different 
sugars
Discussion
The significant reduction of blood glucose level 
showed M. charantia extract had blood glucose 
lowering effect in the diabetics. M. charantia extract 
at 200 mg/kg body weight was more effective than 
100 mg/kg body weight since the former dosage 
reduced blood glucose level to near normal value. 
Thus, the M.charantia extract at the dosage of 200 
mg/kg body weight had a higher hypoglycaemic 
effect in this study.
 Takasu et al. (1991) reported that streptozotocin 
induces diabetes in rat by β cell destruction, through 
generation of free radicals, which cause alkylation 
of DNA and subsequently increase blood glucose 
level. The rats were considered diabetic if their 
blood glucose levels were more than 13.9 mmol/L 
after 3 days due to β cell destruction, through 
generation of free radicals which cause alkylation 
of DNA and subsequently increase blood glucose 
level (Thirumalai et al., 2011). In the present study, 
injection of STZ induced diabetic condition since 
the blood glucose levels of rats were more than 13.9 
mmol/L. 
Previous study by Yuan et al. (2008) showed that 
a water-soluble hypoglycemic peptide in Momordica 
charantia L. Var. abbreviata Ser. (MCV) aqueous 
extract at a dose of 2 mg/kg significantly lowered 
blood glucose level in alloxan-induced diabetic mice. 
Zhao et al. (2005) also reported crude saponins in 
MCV could significantly lower the blood glucose 
level in alloxan-induced diabetic mice.
As shown in Figure 3(A), there were higher levels 
of lactate and glucose in urine samples of diabetic rat. 
On the other hand, normal and M. charantia treated 
diabetic rats had higher levels of succinate, creatine, 
creatinine, urea and phenylacetylglycine. Diabetic 
rat exhibited higher levels of glucose in urine due 
to decreased glucose metabolism and increased 
glucose production resulting from STZ injection and 
subsequently hyperglycemia . Zhang et al. (2008) 
also reported increased levels of glucose in urine 
of STZ-induced diabetic rat due to gluconeogenesis 
and glycogenolysis. Besides that, Zhang et al. (2008) 
reported a significantly or moderately increased level 
of urea in diabetic rats and this relationship suggests 
enhanced amino acids-fueled gluconeogenesis in the 
diabetic that lead to increased nitrogen load to the 
liver where urea is formed. However, the present 
study demonstrated contrary result to that of Zhang et 
al. (2008) in which urea level reduced in diabetic rats 
but support the study by Guan et al.(2013) where the 
urea level was significantly decreased after the 15th 
week of STZ injection. Low concentration of urea 
suggested a reduced turnover of protein in diabetic 
treated rats (He et al., 2012). Thus, it indicated a 
reflect in glomerular filtration rate and worsened the 
renal function (Guan et al., 2013).
Enhanced lactate level in urine of diabetic 
indicates reduced consumption of lactate compared 
to its production. It was consistent with previous 
work by Zhang et al. (2008) that demonstrated 
severely increased lactate level in the diabetic urine. 
Elevated level of lactate in diabetic urine indicates 
an increased glycolysis. This resulted from a 
deficiency of muscle glucose that lead to oxidation 
of all the carbon from glucose through oxidative 
phosphorylation, higher level of lactate instead came 
from the glycolic production of lactate in red blood 
cells, which express a variant of the enzyme lactate 
dehydrogenase (Wiback et al., 2002).
Succinate, which is an intermediate of Krebs 
cycle, presented in decreased level in urine samples 
of diabetic rat. The present result supported by 
previous studies by Zhao et al. (2010) that also 
reported reduction in level of succinate in urine 
samples of diabetic rats. Since succinate that involved 
in energy metabolism was perturbed resulted from 
hyperglycemia and hypoinsulinemia after STZ 
injection, energy metabolism was also altered, as well 
as impairment in mitochondrial function or activity 
due to increased blood glucose (Waters et al., 2005).
Level of creatine was also reduced in the urine 
samples of diabetic. This result was consistent with 
previous work by Zhao et al. (2011) that explained the 
observation might be due to factors such as creatine 
reabsorption, altered renal function and morphology 
resulted from diabetic nephropathy, which is one of 
the manifestations of diabetic systemic microvascular 
disease. The clearance of creatine and creatinine 
measured as an indicator of glomerular filtration rate. 
Decreased levels of urinary creatine and creatinine 
are considered as markers of renal function. STZ was 
reported to have a direct damaging effect on some 
organs, such as kidney and liver (Elsner et al., 2000). 
The present study showed that the deleterious action 
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of STZ on renal function might lead to alteration 
in urinary excretion of these metabolites in STZ-
induced diabetic rats. On the other hand, normal rats 
had higher levels of creatine and creatinine in the 
urine as these metabolites passed out efficiently due 
to normal function of their kidneys.
Higher level of phenylacetylglycine (PAG) in 
urine of normal and M. charantia treated diabetic 
groups was observed in this study. According to 
Wikoff et al. (2009) production of PAG could be 
attributed to gut microbial activity. Moreover, liver 
also plays an important role in the production of 
PAG. PAG was formed from conjugation of their 
precursor acids with glycine in hepatic mitochondria. 
The alteration of PAG production indicated the 
malfunction of liver (Kasuya et al., 2000).
Normal rats had higher levels of citrate in urine. 
Citrate is excreted in urine due to its important role 
as an inhibitor of calcium salt crystallization. Citrate 
forms complex with calcium ions in urine, reducing 
calcium ion activity and subsequently reduces 
urinary supersaturation of calcium phosphate and 
calcium oxalate (Rodger et al., 2006). Low amount 
of citrate in urine or hypocitraturia, is a risk factor 
for kidney stone formation. In addition, citrate is 
often the most abundant organic acid in urine. Higher 
levels of creatine and creatinine were found in urine 
of normal rats. Although less creatine and creatinine 
were found in M. charantia treated rats, the amount of 
both metabolites was higher in M. charantia treated 
rats compared to diabetic rats as explained earlier. 
According to Deguchi et al. (2005) hippurate 
is a harmful uremic toxin that accumulates during 
chronic renal failure. It is a glycine conjugate of 
benzoate and formed mainly by gut flora from 
aromatic amino acids. The primary pathway for 
its elimination from the plasma via kidney is the 
active tubular secretion. Functional failure of this 
system might lead to accumulation of hippurate 
in blood (Tsutsumi et al., 2002). Therefore, 
normal level of hippurate in the urine indicated 
healthy renal function to eliminate this uremic 
toxin.                                                                                                                  
In the present study, administration of M. 
charantia fruit extract to diabetic rats was able to 
shift the metabolites profile of diabetic rat closer to 
normal level as shown were clustered in the PLS-DA 
score plot along PLS component 1 (Figure 2).This 
could be attributed to the ability of M. charantia 
fruits extract in regulating of some altered metabolic 
pathways involved in diabetes. Although the glucose 
level of M. charantia fruits treated rats were the same 
as normal rats, some metabolites were not shifted to 
normal level. It suggested that the use of M. charantia 
fruits could not lead the urine profile back totally to 
normal except glucose, succinate, lactate, creatine, 
creatinine, urea and phenylacetylglycine level. 
Conclusion
1H-NMR-based metabolomics analysis of 
urine samples showed some metabolism alteration 
involved in diabetes. Such altered metabolic pathways 
were glycolysis, Krebs cycle, protein and creatine 
metabolism. The administration of M. charantia fruits 
extract was able to partially fix the altered metabolism 
of diabetic rats as indicated by the shifting of some 
metabolites profile (glucose, succinate, lactate, 
creatine, creatinine, urea and phenylacetylglycine) 
to normal level. Hence, this extract demonstrated to 
be potential anti-type 1 diabetic agent, as it able to 
alter the main pathway leading to diabetic condition 
in treated rats although not all metabolites were 
shifted to normal level. Further studies are required 
to normalized those remain metabolites such as the 
evaluation of synergism effect of this plant with 
other medicinal plants on anti-diabetic activity, 
and enhancement of anti-diabetic compounds in M. 
charantia fruits extract by optimization of extraction, 
harvesting and storage conditions.
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